META 001 PH
Alternative Names: META-001-PHLatest Information Update: 19 Sep 2024
Price :
$50 *
At a glance
- Originator META Pharmaceuticals
- Class Small molecules; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Primary hyperoxaluria
Most Recent Events
- 05 Aug 2024 Preclinical trials in Primary hyperoxaluria in China (unspecified route)
- 05 Aug 2024 US FDA grants Rare Pediatric Disease Designation (RPDD) to META 001 PH for primary hyperoxaluria in USA
- 05 Aug 2024 Pharmacodynamics and adverse events data from preclinical trial in Primary hyperoxaluria released by META Pharmaceuticals